Zobrazeno 1 - 10
of 44
pro vyhledávání: '"Gary B Gordon"'
Autor:
Michael J Newman, Jeffery A Nieves, Gary B Gordon, Diana L Hanna, Angela T Alistar, Mohammed NAl Hallak, Roger J Waltzman
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 2 (2023)
Externí odkaz:
https://doaj.org/article/1066c9ece15f42a689682e4141b44383
Autor:
Meredith Buxton, Donald A. Berry, Gary B. Gordon, Erik P. Sulman, G B M Agile Investigators, Michael Weller, Webster K. Cavenee, Kirk Tanner, Mustafa Khasraw, Ingo K. Mellinghoff, Andrew B. Lassman, Patrick Y. Wen, Michael Lim, Timothy F. Cloughesy, W. K. Alfred Yung, Benjamin M. Ellingson, Wenbin Lee, John de Groot, James Perry, Brian M. Alexander, Howard Colman
Publikováno v:
Neuro Oncol
Developing new therapies for patients with glioblastoma (GBM) requires focused interaction between industry, academia, nonprofits, patient advocacy, and health authorities, and novel approaches to clinical trials. GBM Adaptive Global Innovative Learn
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b701b2a693fe7768971406bfd39415f
https://europepmc.org/articles/PMC7651338/
https://europepmc.org/articles/PMC7651338/
Autor:
Donald A. Berry, Wenbin Li, Gary B. Gordon, Webster K. Cavenee, Gbm Agile Investigators, Meredith Buxton, Benjamin M. Ellingson, Andrew B. Lassman, James Perry, Michael Lim, Kirk Tanner, Erik P. Sulman, Patrick Y. Wen, Timothy F. Cloughesy, Michael Weller, Mustafa Khasraw, Ingo K. Mellinghoff, John de Groot, W. K. Alfred Yung, Howard Colman, Brian M. Alexander
Publikováno v:
Journal of Clinical Oncology. 38:TPS2579-TPS2579
TPS2579 Background: Glioblastoma (GBM) is an aggressive brain tumor with few effective therapies and is invariably fatal. Developing new therapies for patients with GBM requires focused interaction between industry, academia, nonprofits, patient advo
Autor:
Gary B. Gordon, Magdalena Bynum
Publikováno v:
Analytical Chemistry. 76:7039-7044
DNA microarrays produce their greatest sensitivities when hybridized using concentrated samples and effective mixing; however, these goals have proved elusive to combine. If samples are diluted enough to fill larger chambers, then mixing works well u
Autor:
Yuesheng Zhang, Gary B. Gordon
Publikováno v:
Molecular Cancer Therapeutics. 3:885-893
Many genes, with products involved in the protection of cells against carcinogens, oxidants, and other toxic chemicals, are under the transcriptional control of a simple DNA regulatory element [i.e., the antioxidant response element (ARE)]. One or mo
Autor:
Robin K. S. Phillips, Brian P. Saunders, Yu Shen, Stuart O. Zimmerman, Ernest T. Hawk, Gideon Steinbach, L-K. Su, N. Wakabayashi, Marina Wallace, Jeffrey W. Sherman, G. Kelloff, Gary B. Gordon, M. Rodrigues-Bigas, L. Godio, Patrick M. Lynch, Bernard Levin
Publikováno v:
Gut. 50:857-860
Background: Non-selective cyclooxygenase (COX) inhibitors (non-steroidal anti-inflammatory drugs) inhibit large bowel carcinogenesis in patients with familial adenomatous polyposis (FAP). Their role in the duodenum of these patients is less certain.
Autor:
Hao, Xiong, Rajendra S, Pradhan, Adel, Nada, Andrew P, Krivoshik, Kyle D, Holen, James W, Rhodes, Gary B, Gordon, Rod, Humerickhouse, Walid M, Awni
Publikováno v:
Anticancer research. 34(7)
Biopharmaceutical studies for anti-cancer drugs are typically conducted in cancer patients due to unacceptable toxicities to healthy volunteers. Navitoclax is a first-in-class, orally bioavailable, targeted Bcl-2 family protein inhibitor that has bee
Autor:
Gary B. Gordon, Bruce P. Mosier, Joshua I. Molho, Bijan Mohammadi, Thomas W. Kenny, Reid A. Brennen and, and Juan G. Santiago, Amy E. Herr
Publikováno v:
Analytical Chemistry. 73:1350-1360
Chip-based microcolumn separation systems often require serpentine channels to achieve longer separation lengths within a compact area. However, analyte bands traveling through curved channels experience an increased dispersion that can reduce the be
Autor:
Thomas W. Kensler, Hans J. Prochaska, Shuang Yuan Kuang, Baibai Chen, Jia-Sheng Wang, Geng Sun Qian, Mary B. Gorman, John D. Groopman, Xia He, Yuan Rong Zhu, Bao Chu Zhang, Audrey Zarba, Lu Yi Yu, Kathy J. Helzlsouer, Patricia A. Egner, Yan Wu, Xi Fang, Alvaro Muñoz, Yan Feng Li, Cheryl Enger, Lisa P. Jacobson, Gary B. Gordon, Jin Bing Wang, Silvio De Flora, Qi Nan Zhang, Nancy E. Davidson
Publikováno v:
Journal of Cellular Biochemistry. 67:166-173
Oltipraz has been used clinically in many regions of the world as an antischistosomal agent and is an effective inhibitor of aflatoxin hepatocarcinogenesis in rats. This chemopreventive action of oltipraz results primarily from an altered balance in
Autor:
Lee J. Helman, Gary B. Gordon, Seth M. Steinberg, James H. Doroshow, Shivaani Kummar, Jerry M. Collins, Larry Rubinstein, Anne Monks, Robert J. Kinders, Helen Eliopoulos, Robert H. Wiltrout, Jennifer A. Low, Anthony J. Murgo, Lawrence R. Phillips, Martin Gutierrez, Joseph E. Tomaszewski, Ralph E. Parchment, Vincent L. Giranda, Jiuping Ji, Alice P. Chen
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(16)
Purpose We conducted the first phase 0 clinical trial in oncology of a therapeutic agent under the Exploratory Investigational New Drug Guidance of the US Food and Drug Administration. It was a first-in-human study of the poly (ADP-ribose) polymerase